No added benefits in slowing MS disability progression were found in a study that increased Ocrevus dosing to 2-3 times the ...

Roche Holding AG said a high-dose version of Ocrevus, its best-selling multiple sclerosis drug, failed to outperform the ...

“These findings reaffirm that the current Ocrevus IV 600 mg is optimally dosed to significantly slow disability progression,” ...

Roche said on Wednesday that a trial testing higher doses of its multiple sclerosis drug Ocrevus did not show an efficacy ...

The study aimed to determine whether treatment with high dose ocrelizumab would provide an additional benefit in slowing disability progression.

Roche’s phase III MUSETTE trial of Ocrevus high dose in people with relapsing multiple sclerosis fails to meet primary endpoint: Basel Friday, April 4, 2025, 11:00 Hrs [IST] Roc ...

The cost of Ocrevus can vary based on several factors, including your insurance coverage. Coupons and drug savings programs can also lower the price you’ll pay for Ocrevus. As with all ...

Swiss pharma giant Roche RHHBY faced a setback in its efforts to develop a higher dose of multiple sclerosis drug Ocrevus (ocrelizumab). The company announced that a phase III study, MUSETTE ...

Dow Jones Newswires is a market-moving financial and business news source, used by wealth managers, institutional investors and fintech platforms around the world to identify trading and investing ...

Roche's MUSETTE trial found no additional benefit of high-dose Ocrevus over the 600 mg IV dose, reaffirming its efficacy and ...

MUSETTE trial was designed to determine whether a higher dose of the currently approved Ocrevus IV 600 mg would provide additional benefit to people living with relapsing multiple sclerosis ...

The CNS market’s decade-long stagnation was driven by the high cost, complexity, and risk of drug development.